\r\n![\"Bio-Rad](\"https:\/\/clixtrac.com\/banner\/311442.jpg\" "\\"Bio-Rad")
<\/a>\r\n<\/p>\n<\/div><\/section><\/div>
![\"\"](\"https:\/\/clixtrac.com\/banner\/283809.png\" "\\"\\"")
<\/a>\r\n<\/div><\/p>\n<\/div><\/section>\n
Siemens Healthineers to distribute Scopio Labs\u2019 full-field digital cell morphology technology<\/h1>E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\nSiemens Healthineers to distribute Scopio Labs\u2019 full-field digital cell morphology technology<\/h4>\n
Siemens Healthineers has agreed to distribute Scopio Labs\u2019 full-field digital cell morphology technology, which will enable clinical labs to examine patient blood cell samples digitally instead of under a microscope. The Scopio X100 and Scopio X100HT imaging platforms will complement the Siemens Healthineers systems \u2013 including the Atellica HEMA 570 and Atellica HEMA 580 Analyzers \u2013 to offer labs high-resolution, full-field viewing for peripheral blood specimens and artificial intelligence-based morphological analysis with remote capabilities through the secure hospital network.<\/h3>\n<\/p>\n
\u201cBy offering laboratorians access to novel digital haematology technologies in one of the lab\u2019s busiest testing disciplines, we will be providing critical tools to optimize operational workflow and laboratory efficiency, accelerate diagnosis, and improve patient care while addressing reduced resource capacity,\u201d said Sharon Bracken, Head of Diagnostics, Siemens Healthineers. \u201cThe alliance between Siemens Healthineers and Scopio Labs is a step forward in delivering automated and digitized solutions that would redefine haematology workflow.\u201d<\/p>\n<\/div><\/section>
\n
<\/div><\/div><\/div>
\nThe Scopio digital cell morphology platforms are intended for use in the central laboratory adjacent to haematology analyzers to examine patient blood cell samples digitally and remotely, instead of on a slide under a microscope. A patient sample is run on a haematology analyzer. When abnormalities in a patient blood sample are detected or further analysis is required, a blood smear is prepared, and the slide is transferred to the Scopio imaging platform for digitalization. Traditional manual microscopy requires specialized laboratory staff to examine slides and is time-consuming due to the volume of testing and the scope of analysis required for abnormal patient samples. Attempts to digitize cell samples have often faced a tradeoff \u2013 increasing resolution versus field of view \u2013 both of which contain essential clinical information pertinent for patient care.<\/p>\n
Scopio Labs\u2019 full-field imaging technology provides both the clinical big picture and the smallest details of a cell at the same time. Integrated AI decision support gives laboratory professionals a highly efficient way to standardize WBC differentials, RBC blood morphology, and platelet estimations. Remote review capabilities mean laboratory professional expertise will no longer be limited by physical location, and healthcare networks can provide fast analyses for their patients while better managing professional resources at their institutions. Scopio\u2019s Full-Field Peripheral Blood Smear Application has been shown to reduce turnaround time for peripheral blood smear review by 60% \u2013 a significant optimization of lab workflows and operational efficiencies [1].<\/p>\n
Itai Hayut, CEO and cofounder of Scopio Labs, commented: \u201cWith Siemens Healthineers\u2019 strong focus on data-driven clinical decision-making and our shared mission to innovate and shape the future of haematology, we are excited to include our Full-Field Cell Morphology imaging and analysis platforms as a part of their extensive laboratory diagnostics portfolio. This partnership will help accelerate digital workflow transformation in haematology laboratories worldwide to enhance clinical decisions for optimal patient care.\u201d<\/p>\n
The X100HT can meet the turnaround time requirements of large hospitals and labs, offering throughput of up to 40 samples per hour. The X100 offers a throughput of up to 15 samples per hour. The Full-Field Peripheral Blood Smear Application on the X100HT and the X100 is available for sale in US and EU.<\/p>\n
References:<\/strong><\/em>
\n1. Katz B-Z, et al. Evaluation of Scopio Labs X100 Full Field PBS: The first high-resolution full field viewing of peripheral blood specimens combined with artificial intelligence-based morphological analysis. Int J Lab Hematol. 2021;00:1\u20139. https:\/\/doi.org\/10.1111\/ijlh.13681<\/a><\/em><\/p>\n<\/div><\/section>
\n
Siemens Healthineers to distribute Scopio Labs\u2019 full-field digital cell morphology technology<\/h4>\n
Siemens Healthineers has agreed to distribute Scopio Labs\u2019 full-field digital cell morphology technology, which will enable clinical labs to examine patient blood cell samples digitally instead of under a microscope. The Scopio X100 and Scopio X100HT imaging platforms will complement the Siemens Healthineers systems \u2013 including the Atellica HEMA 570 and Atellica HEMA 580 Analyzers \u2013 to offer labs high-resolution, full-field viewing for peripheral blood specimens and artificial intelligence-based morphological analysis with remote capabilities through the secure hospital network.<\/h3>\n<\/p>\n
\u201cBy offering laboratorians access to novel digital haematology technologies in one of the lab\u2019s busiest testing disciplines, we will be providing critical tools to optimize operational workflow and laboratory efficiency, accelerate diagnosis, and improve patient care while addressing reduced resource capacity,\u201d said Sharon Bracken, Head of Diagnostics, Siemens Healthineers. \u201cThe alliance between Siemens Healthineers and Scopio Labs is a step forward in delivering automated and digitized solutions that would redefine haematology workflow.\u201d<\/p>\n<\/div><\/section>
\n
<\/div><\/div><\/div>
\nThe Scopio digital cell morphology platforms are intended for use in the central laboratory adjacent to haematology analyzers to examine patient blood cell samples digitally and remotely, instead of on a slide under a microscope. A patient sample is run on a haematology analyzer. When abnormalities in a patient blood sample are detected or further analysis is required, a blood smear is prepared, and the slide is transferred to the Scopio imaging platform for digitalization. Traditional manual microscopy requires specialized laboratory staff to examine slides and is time-consuming due to the volume of testing and the scope of analysis required for abnormal patient samples. Attempts to digitize cell samples have often faced a tradeoff \u2013 increasing resolution versus field of view \u2013 both of which contain essential clinical information pertinent for patient care.<\/p>\n
Scopio Labs\u2019 full-field imaging technology provides both the clinical big picture and the smallest details of a cell at the same time. Integrated AI decision support gives laboratory professionals a highly efficient way to standardize WBC differentials, RBC blood morphology, and platelet estimations. Remote review capabilities mean laboratory professional expertise will no longer be limited by physical location, and healthcare networks can provide fast analyses for their patients while better managing professional resources at their institutions. Scopio\u2019s Full-Field Peripheral Blood Smear Application has been shown to reduce turnaround time for peripheral blood smear review by 60% \u2013 a significant optimization of lab workflows and operational efficiencies [1].<\/p>\n
Itai Hayut, CEO and cofounder of Scopio Labs, commented: \u201cWith Siemens Healthineers\u2019 strong focus on data-driven clinical decision-making and our shared mission to innovate and shape the future of haematology, we are excited to include our Full-Field Cell Morphology imaging and analysis platforms as a part of their extensive laboratory diagnostics portfolio. This partnership will help accelerate digital workflow transformation in haematology laboratories worldwide to enhance clinical decisions for optimal patient care.\u201d<\/p>\n
The X100HT can meet the turnaround time requirements of large hospitals and labs, offering throughput of up to 40 samples per hour. The X100 offers a throughput of up to 15 samples per hour. The Full-Field Peripheral Blood Smear Application on the X100HT and the X100 is available for sale in US and EU.<\/p>\n
References:<\/strong><\/em>
\n1. Katz B-Z, et al. Evaluation of Scopio Labs X100 Full Field PBS: The first high-resolution full field viewing of peripheral blood specimens combined with artificial intelligence-based morphological analysis. Int J Lab Hematol. 2021;00:1\u20139. https:\/\/doi.org\/10.1111\/ijlh.13681<\/a><\/em><\/p>\n<\/div><\/section>
\n
\n
<\/div><\/div><\/div>\n
The Scopio digital cell morphology platforms are intended for use in the central laboratory adjacent to haematology analyzers to examine patient blood cell samples digitally and remotely, instead of on a slide under a microscope. A patient sample is run on a haematology analyzer. When abnormalities in a patient blood sample are detected or further analysis is required, a blood smear is prepared, and the slide is transferred to the Scopio imaging platform for digitalization. Traditional manual microscopy requires specialized laboratory staff to examine slides and is time-consuming due to the volume of testing and the scope of analysis required for abnormal patient samples. Attempts to digitize cell samples have often faced a tradeoff \u2013 increasing resolution versus field of view \u2013 both of which contain essential clinical information pertinent for patient care.<\/p>\n
Scopio Labs\u2019 full-field imaging technology provides both the clinical big picture and the smallest details of a cell at the same time. Integrated AI decision support gives laboratory professionals a highly efficient way to standardize WBC differentials, RBC blood morphology, and platelet estimations. Remote review capabilities mean laboratory professional expertise will no longer be limited by physical location, and healthcare networks can provide fast analyses for their patients while better managing professional resources at their institutions. Scopio\u2019s Full-Field Peripheral Blood Smear Application has been shown to reduce turnaround time for peripheral blood smear review by 60% \u2013 a significant optimization of lab workflows and operational efficiencies [1].<\/p>\n
Itai Hayut, CEO and cofounder of Scopio Labs, commented: \u201cWith Siemens Healthineers\u2019 strong focus on data-driven clinical decision-making and our shared mission to innovate and shape the future of haematology, we are excited to include our Full-Field Cell Morphology imaging and analysis platforms as a part of their extensive laboratory diagnostics portfolio. This partnership will help accelerate digital workflow transformation in haematology laboratories worldwide to enhance clinical decisions for optimal patient care.\u201d<\/p>\n
The X100HT can meet the turnaround time requirements of large hospitals and labs, offering throughput of up to 40 samples per hour. The X100 offers a throughput of up to 15 samples per hour. The Full-Field Peripheral Blood Smear Application on the X100HT and the X100 is available for sale in US and EU.<\/p>\n
References:<\/strong><\/em>
\n1. Katz B-Z, et al. Evaluation of Scopio Labs X100 Full Field PBS: The first high-resolution full field viewing of peripheral blood specimens combined with artificial intelligence-based morphological analysis. Int J Lab Hematol. 2021;00:1\u20139. https:\/\/doi.org\/10.1111\/ijlh.13681<\/a><\/em><\/p>\n<\/div><\/section>
\n